Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events

CONCLUSION: This analysis demonstrates that more frequent assessment of patient-reported symptomatic adverse events will lead to improved detection, and therefore a more complete understanding of the tolerability of experimental anti-cancer therapies.PMID:35575012 | DOI:10.1177/17407745221093935

Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Bellinda L King-Kallimanis Vishal Bhatnagar Erica G Horodniceanu Ting-Yu Chen Paul G Kluetz Source Type: research